Indeed, inhibition ofDPP-4 with vildagliptin improved the glycemic control of type 2 diabetes byimproving the activity of GIP, GLP-1 and pituitary adenylate cyclase activatingpeptide with concomitant improvement in cell function [80]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.